Semax: The ACTH(4-10) Analogue — Mechanism, Cognitive Benefits & Neuroprotection Research

What is Semax?

Semax (Met-Glu-His-Phe-Pro-Gly-Pro; MEHFPGP) is a synthetic heptapeptide analogue of the ACTH(4-10) fragment of adrenocorticotropic hormone. It was developed by the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s as part of a long-running programme to derive CNS-active, metabolically stable peptides from the ACTH and melanocortin superfamily.

The critical structural innovation in Semax is the addition of a Pro-Gly-Pro tripeptide to the C-terminus of the ACTH(4-7) core. This extension dramatically increases resistance to peptidases compared to native ACTH fragments, extending the active half-life from minutes to hours in CNS tissue. The result is a compound that retains the nootropic ACTH fragment activity while shedding the adrenal-stimulating properties of full-length ACTH — giving researchers a selective CNS tool [1][2].

Semax has a notably extensive published literature by peptide research standards. It has been studied in Russia as a licensed pharmaceutical for stroke, neurological disorders, and cognitive impairment — and was approved by the Russian Ministry of Health in 1994. This clinical use has generated a significant body of human data that is unusual for a research peptide, most of which exists in Russian-language literature but with an increasing number of English-language publications [3][4].

How it works: mechanism of action

Semax operates through several interconnected CNS pathways that have been characterised across multiple independent research groups.

Melanocortin receptor activation

The ACTH(4-10) core of Semax binds to melanocortin receptors (MCR) — particularly MC4R and MC5R — in the hippocampus, prefrontal cortex, and other CNS structures relevant to cognition and emotion. MC4R activation in the hippocampus is linked to enhanced memory consolidation, reduced anxiety, and increased neuroplasticity. This receptor specificity means Semax exerts its effects centrally without engaging the adrenal MC2R receptor responsible for cortisol release — a key safety distinction versus full ACTH [1][2].

BDNF upregulation: the neuroplasticity core

Perhaps the most significant and reproducible finding in the Semax literature is its ability to dramatically upregulate BDNF (brain-derived neurotrophic factor). BDNF is the master neurotrophin for synaptic plasticity, neuron survival, and the formation of new synaptic connections. Studies in rodents consistently show that Semax administration raises hippocampal BDNF mRNA expression by 3- to 5-fold within hours of administration, with effects lasting 24–72 hours [5].

This BDNF upregulation has downstream consequences: BDNF activates TrkB receptors, triggering MAPK/ERK and PI3K/Akt pathways that enhance synaptic strength, promote neuronal survival, and drive long-term potentiation (LTP) — the cellular correlate of learning and memory. In neuroprotective contexts, this BDNF surge helps neurons in injured brain regions resist apoptosis and maintain functional connectivity [5][6].

Monoamine system activation

Eremin et al. (2005) demonstrated that Semax activates both dopaminergic and serotonergic systems in rat forebrain. Dopamine turnover increased in the striatum and limbic structures; serotonin turnover increased in the frontal cortex and hippocampus. These monoamine effects parallel the activity of conventional nootropic agents and antidepressants, but through a distinct upstream peptidergic mechanism. The dual monoamine activation is thought to underpin Semax's reported effects on attention, motivation, and mood in research settings [2].

Antioxidant and anti-inflammatory activity

Medvedeva et al. (2009) showed that Semax reduces markers of oxidative stress in brain tissue under conditions of experimentally induced hypoxia. The peptide increases activity of endogenous antioxidant enzymes (superoxide dismutase, catalase) and reduces lipid peroxidation products. This anti-inflammatory profile complements the BDNF mechanism, creating a combined neuroprotective environment that is particularly relevant in ischaemic injury research [6].

Documented research benefits

Neuroprotection in ischaemic injury

This is the most extensively documented area of Semax research, supported by both animal studies and clinical data. In rat middle cerebral artery occlusion (MCAO) models — the standard preclinical ischaemic stroke model — Semax treatment reduced infarct volume, preserved neurological function scores, and reduced apoptotic cell death in the penumbra zone compared to vehicle controls. The neuroprotection is attributed to the combination of BDNF upregulation, anti-inflammatory activity, and direct anti-apoptotic effects [3][4].

Skvortsova et al. (2006) conducted clinical trials of intranasal Semax in acute ischaemic stroke patients. Treated patients showed improved neurological recovery scores at 10 days and 30 days compared to standard-care controls, with the researchers reporting statistically significant benefits on motor function and consciousness assessments. This human data is remarkable for a peptide outside mainstream pharmaceutical development [3].

Cognitive enhancement

Multiple preclinical studies demonstrate improved performance in spatial memory, avoidance learning, and attention tasks following Semax administration in rodents. The effects appear to be mediated by the BDNF upregulation and monoamine activation described above. In one study, a single Semax administration improved maze learning performance by up to 40% compared to controls in aged rats — an effect not seen with vehicle [1][2].

Human data for cognitive enhancement is more limited but includes studies in subjects with mild cognitive impairment and healthy volunteers undergoing high cognitive load tasks. Improvements in attention span, working memory, and processing speed have been reported, though these studies are generally small and conducted primarily in Russian institutions [3].

Anxiety modulation

Kaplan et al. studied Semax's effects on the psychophysiological stress response in healthy volunteers undergoing their first professional performance experience (medical students giving their first injection). Semax administration attenuated EEG markers of anxiety, reduced cortisol response, and improved performance quality compared to placebo. This anxiolytic-without-sedation profile is consistent with MC receptor modulation in limbic structures [1].

ADHD-relevant cognitive models

The dopaminergic activation profile of Semax has made it a candidate for study in ADHD-relevant preclinical models. Semax administration in SHR (spontaneously hypertensive) rats — a standard ADHD model — improved attentional performance and reduced hyperactivity markers. The researchers proposed that Semax's combined dopaminergic and BDNF effects may address multiple aspects of the ADHD neurochemical phenotype simultaneously [2].

Dosing ranges in published literature

The human clinical doses (12–18 μg/kg) are considerably lower than the preclinical animal doses on a per-weight basis. This is not unusual for peptide compounds and may reflect differences in CNS bioavailability between routes, species pharmacokinetics, and the greater sensitivity of human subjects. Research protocols should always reference the primary literature for the specific application under study.

Administration routes & reconstitution

Routes studied in published literature

• Intranasal (IN) — primary route in human clinical studies; nose-to-brain transport via olfactory epithelium bypasses the blood-brain barrier and allows direct CNS delivery; used in stroke and cognitive impairment clinical trials
• Subcutaneous (SC) — dominant route in preclinical animal studies; consistent absorption and well-characterised pharmacokinetics in rodent models

Reconstitution protocol (lyophilised powder)

Semax is supplied as a lyophilised (freeze-dried) powder. Standard laboratory reconstitution uses bacteriostatic water (0.9% benzyl alcohol in sterile water for injection), which is included with the Enhanced Pharma product.

1. Allow the sealed vial to reach room temperature before opening
2. Add bacteriostatic water slowly down the inner wall of the vial — do not inject directly onto the powder
3. Gently swirl until fully dissolved; do not vortex or shake
4. Store reconstituted solution at 2–8°C, protected from light
5. Use within 28 days of reconstitution; discard if cloudy or discoloured

Storage of lyophilised Semax (unopened)

Semax is sensitive to temperature and light. The Enhanced Pharma product is nitrogen-filled to prevent oxidation. Store at 2–8°C, do not freeze. Freezing lyophilised Semax can damage the powder structure and reduce reconstitution quality. Protect from light at all times.

Side effects and safety data

Semax has a relatively well-characterised safety profile compared to most research peptides, owing to its history of clinical use in Russia. The overall tolerability is considered favourable, though formal large-scale human safety data are limited outside the Russian clinical literature.

Reported effects in human clinical studies

• Generally well tolerated at intranasal doses of 12–18 μg/kg in clinical trials; no serious adverse events attributed to Semax in published studies
• Mild local irritation with intranasal administration in some subjects — transient nasal discomfort or mild rhinorrhoea reported in a small proportion of intranasal trial participants
• Mild fatigue or sleep changes reported in some user surveys — these are consistent with CNS-active peptides affecting monoamine systems
• Headache — reported in a minority of cases; mechanism unclear but potentially related to initial dopaminergic activation

Preclinical toxicology

Acute and subchronic toxicology studies in rodents do not show organ toxicity at research doses. At very high doses (many orders of magnitude above research ranges), non-specific CNS excitation has been observed in animal models. No genotoxicity or carcinogenicity signals have been reported at standard doses [1][3].

Interactions & contraindications

• Dopaminergic agents (potential additive effect) — Semax activates dopamine turnover; co-administration with dopamine agonists, MAOIs, or dopamine precursors may produce additive effects; research protocols involving such combinations warrant careful design
• Serotonergic agents — Semax increases serotonin turnover; combination with serotonergic compounds (SSRIs, 5-HT agonists) carries potential for additive serotonergic activity; monitor for serotonin syndrome risk in research designs
• Anticoagulants (theoretical consideration) — in stroke protocols, Semax is used alongside standard stroke care including anticoagulation; no direct interaction is reported, but research protocols in vascular models should account for haemostatic context
• BDNF-modulating compounds — compounds that upregulate or depend on BDNF signalling (exercise, antidepressants, ketamine) may produce additive or complex interactions with Semax's BDNF mechanism; this is largely unexplored territory

Storage & stability

Important: The Enhanced Pharma product label explicitly states do not freeze. The lyophilised powder is nitrogen-filled to prevent oxidation and should be stored refrigerated (2–8°C) at all times. Freezing can disrupt the lyophilised cake structure and impair reconstitution quality.

Frequently asked questions

What is Semax and how is it different from ACTH?

Semax is a synthetic heptapeptide (MEHFPGP) derived from the ACTH(4-10) fragment with a Pro-Gly-Pro C-terminal extension for metabolic stability. Unlike native ACTH, Semax does not stimulate cortisol release — its activity is confined to CNS-relevant MC4R/MC5R receptors. This makes it a selective nootropic without the adrenal side effects of full ACTH [1][2].

What is the evidence for Semax in stroke recovery?

Multiple Russian clinical studies have investigated Semax in ischaemic stroke. Skvortsova et al. (2006) found that intranasal Semax in acute ischaemic stroke patients improved neurological outcomes and reduced infarct volume markers compared to controls. The neuroprotective mechanism involves BDNF upregulation and reduced apoptosis in the penumbra zone [3][4].

Can Semax be used intranasally?

Yes — intranasal administration is one of the primary routes in published Semax literature. The olfactory pathway allows direct nose-to-brain transport, bypassing the blood-brain barrier. This is the route used in several published Russian clinical studies on stroke and cognitive impairment [1][3].

How does Semax upregulate BDNF?

Semax acts on melanocortin receptors (MC4R and MC5R) in the CNS, triggering downstream signalling that increases BDNF gene transcription. Studies show hippocampal BDNF mRNA expression rises 3–5 fold within hours of administration. This BDNF surge promotes neuroplasticity, synaptic strengthening, and neuroprotection [2][5].

Is Semax available in India?

Semax is not an approved pharmaceutical in India. It is available through PEPTIGRID as a research compound for laboratory use only. Contact us via WhatsApp or check our Semax product listing for current pricing. See our introductory peptide guide for more on the Indian research context.